In the past week, RPRX stock has gone up by 1.06%, with a monthly gain of 6.86% and a quarterly surge of 5.14%. The volatility ratio for the week is 3.19%, and the volatility levels for the last 30 days are 2.21% for Royalty Pharma plc The simple moving average for the last 20 days is 2.50% for RPRX’s stock, with a simple moving average of 14.09% for the last 200 days.
Is It Worth Investing in Royalty Pharma plc (NASDAQ: RPRX) Right Now?
Royalty Pharma plc (NASDAQ: RPRX) has a price-to-earnings ratio that is above its average at 13.60x. The stock has a 36-month beta value of 0.48. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RPRX is 342.82M, and at present, short sellers hold a 5.42% of that float. On May 13, 2025, the average trading volume of RPRX was 4.65M shares.
RPRX) stock’s latest price update
Royalty Pharma plc (NASDAQ: RPRX)’s stock price has soared by 0.60 in relation to previous closing price of 33.15. Nevertheless, the company has seen a gain of 1.06% in its stock price over the last five trading days. globenewswire.com reported 2025-05-12 that NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma’s 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Neutral.” The predicted price for RPRX in the upcoming period, according to UBS is $28 based on the research report published on June 03, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see RPRX reach a price target of $47. The rating they have provided for RPRX stocks is “Buy” according to the report published on June 14th, 2022.
Scotiabank gave a rating of “Sector Outperform” to RPRX, setting the target price at $53 in the report published on May 13th of the previous year.
RPRX Trading at 2.65% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.49% of loss for the given period.
Volatility was left at 2.21%, however, over the last 30 days, the volatility rate increased by 3.19%, as shares surge +4.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.86% lower at present.
During the last 5 trading sessions, RPRX rose by +1.06%, which changed the moving average for the period of 200-days by +16.32% in comparison to the 20-day moving average, which settled at $32.54. In addition, Royalty Pharma plc saw 30.73% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for RPRX
Current profitability levels for the company are sitting at:
- 0.84 for the present operating margin
- 1.0 for the gross margin
The net margin for Royalty Pharma plc stands at 0.48. The total capital return value is set at 0.12. Equity return is now at value 16.57, with 6.48 for asset returns.
Based on Royalty Pharma plc (RPRX), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at 0.35. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 7.7.
Currently, EBITDA for the company is 1.29 billion with net debt to EBITDA at 2.8. When we switch over and look at the enterprise to sales, we see a ratio of 9.27. The receivables turnover for the company is 95.19for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.56.
Conclusion
To sum up, Royalty Pharma plc (RPRX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
